Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. - Wikidata - awgldk - TriplyDB

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.

http://www.wikidata.org/entity/Q37426237

about

Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections.In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program

P2860

Q38270642-3A71B828-7BB6-4D54-B779-5467032D37CC Q38394008-6AB06615-8A95-4D0A-B42E-7136F35211D2 Q38987098-AC22C12E-3AA4-43B6-BE37-4AEB5029F489 Q40390434-5607D698-ABE4-422A-A590-DF5F2574F905 Q40766188-27B0E46B-6633-4655-B81C-5751B794D319 Q40976207-08EDFBD4-8B1F-41B2-8F00-52E2B188C907

P2860

Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.

http://www.wikidata.org/entity/Q37426237

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@en

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@nl

type

label

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@en

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@nl

prefLabel

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@en

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@nl

P1433

Q37426237-ACF04B1A-5141-45FD-BC1D-4537F1FD923D

P1476

Q37426237-AD968805-AE32-47D5-ABB9-073AC2EA6BED

P2093

Q37426237-82FF2DCC-01F5-40DD-83E6-175C0BEC105F

Q37426237-913DF2A9-21E9-412F-96AE-0EEF51864E18

Q37426237-A9C9792D-6516-49C5-ABFC-858939C578B2

Q37426237-E6273C96-4514-4351-9005-D3E03DD147D8

Q37426237-E78AFC88-9FA9-41FC-8720-FDBA371B4513

P2860

Q37426237-081FC4FB-A14E-4D8A-B635-6D730CDBF302

Q37426237-1C6D36B5-4F52-4EFF-906B-BB8AA9B88809

Q37426237-2E50689C-D0A6-4026-AF3C-BDB3BA64539A

Q37426237-2FA01FBD-06EE-466D-9AC0-C7E85706E139

Q37426237-45B9A3C5-332F-443B-A983-04DCD7511726

Q37426237-48134F26-8E6D-417D-9ED5-428B5DA09A64

Q37426237-492E5858-87A3-41CE-92AD-F5C28E4F1175

Q37426237-5AD40647-7432-4433-A9E3-104A3EC8ADB9

Q37426237-5DA13A37-FE43-4EBB-AD8F-1003D233F440

Q37426237-62C6AD42-F1C8-4A31-93AF-C6A4D23405E2

P304

Q37426237-6F8CA5FE-3B51-4957-BE78-960EFD7F1292

P31

Q37426237-42E6FD7A-252E-4AEF-BBF2-4C8E2B72195B

P356

Q37426237-88BE7AAF-AABC-465F-9D45-EB6EB25E2C9F

P433

Q37426237-735BD970-4FC1-4EAE-8679-2EA6DE1568CA

P478

Q37426237-077B0726-9E35-4362-AAB0-BF762238CBE1

P577

Q37426237-E280869C-C46F-440B-A9C0-13A3CB4F3E57

P698

Q37426237-43B56011-AC49-47CD-B6EB-0EE1930D0BBA

P932

Q37426237-4C0FD494-24AB-4FFD-9AE3-F8F847CA4C6E

P356

1973947813Y.0000000144

P1433

Journal of Chemotherapy

P1476

Ceftaroline fosamil and treatm ...... ons: CAPTURE study experience.

@en

P2093

Alena Jandourek

http://www.w3.org/2001/XMLSchema#string

Alexander Smith

http://www.w3.org/2001/XMLSchema#string

Amanda Davis

http://www.w3.org/2001/XMLSchema#string

H David Friedland

http://www.w3.org/2001/XMLSchema#string

Paul D Santos

http://www.w3.org/2001/XMLSchema#string

P2860

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients.

A review of linezolid: the first oxazolidinone antibiotic.

Trends in US hospital admissions for skin and soft tissue infections

TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.

Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.

Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis.

Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.

Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

P304

341-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/1973947813Y.0000000144

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24083879

http://www.w3.org/2001/XMLSchema#string

P932

3878396

http://www.w3.org/2001/XMLSchema#string